Publications and presentations
AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
Authors: Toni K. Choueiri, Laurence Albiges, Philippe Barthélémy, Roberto Iacovelli, Sheik Emambux, Javier Molina-Cerrillo, Benjamin Garmezy, Pedro Barata, Arnab Basu, Maria T. Bourlon, Helen Moon, Raffaele Ratta, Rana R. McKay, Alexander Chehrazi-Raffle, Hans Hammers, Daniel Y. C. Heng, Edgar Braendle, Kathryn E. Beckermann, Bradley A. McGregor, Robert J. Motzer. Click here for link to article.
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial | The Oncologist | Oxford Academic
Authors: Kathryn E. Beckermann, Aviva G. Asnis-Alibozek, Michael B. Atkins, Bernard Escudier, Thomas E. Hutson, Vijay Kasturi, David F. McDermott, Sumanta K. Pal, Camillo Porta, Brian I. Rini, Elena Verzoni. Click here for link to article.
Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma (TIVO-3): A Phase 3, Multicentre, Randomised, Controlled, Open-Label Study
Authors: Brian I. Rini, Sumanta K. Pal, Bernard J. Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, David F. McDermott. Request for Reprint of The Lancet Oncology TIVO-3 Manuscript.
Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial
Authors: Pedro C. Barata, Alexander Chehrazi-Raffle, Kimberly D. Allman, Aviva Asnis-Alibozek, Vijay Kasturi, Sumanta K. Pal. Click here for link to article.